Vera Therapeutics (VERA) Stock Forecast & Price Target

Vera Therapeutics is supported by a major regulatory inflection point, as the FDA’s July 7 accelerated approval of Trutakna made it the first approved agent targeting both BAFF and APRIL in IgAN, while the launch is already underway. The core bull case is reinforced by the ORIGIN 3 eGFR readout remaining on track for 3Q26, with a potential 4Q26 sBLA submission that could support full approval in 2027 and improve formulary access, adoption, and payer acceptance. Financially, Vera ended 2Q26 with approximately $499M in cash, cash equivalents, and marketable securities, reported a net loss of $1.52 per share versus consensus of $1.58, and appears sufficiently funded through potential approval and U.S. commercial launch.

Vera Therapeutics is facing a challenging launch because Trutakna enters an IgAN market where Voyxact’s two-year VISIONARY data set a high efficacy bar, with annualized eGFR slope of +0.3 versus -4.2 on placebo and monthly dosing that may be favored over Trutakna’s weekly regimen. Commercially, estimates have been cut to FY26-FY28 revenue of $15M, $191M, and $571M, below consensus, while peak penetration for atacicept was lowered to 15% from 20% amid competition from another entrant possibly arriving in November. The outlook is further pressured by regulatory uncertainty around accelerated approval and labels, plus the likelihood that Vera will need additional funding to fully develop and commercialize atacicept, creating dilution risk if capital markets are inaccessible.